Alnylam Pharmaceuticals, Inc. (ALNY)

358.08 -11.92 (-3.22%) USD  |  NASDAQ  |  Jan 23, 16:00
357.98 -0.10 (-0.03%) After-Hours: 19:29
More

Alnylam Pharmaceuticals CAPEX To Revenue (TTM)

CAPEX To Revenue (TTM) Chart

View CAPEX To Revenue (TTM) for ALNY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View CAPEX To Revenue (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

CAPEX To Revenue (TTM) Range, Past 5 Years

View CAPEX To Revenue (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

CAPEX To Revenue (TTM) Benchmarks

View CAPEX To Revenue (TTM) Benchmarks
Start Trial
Insmed, Inc. Upgrade
Pfizer Inc. Upgrade
Biogen, Inc. Upgrade
Bristol Myers Squibb Co. Upgrade
Vertex Pharmaceuticals, Inc. Upgrade